Literature DB >> 1173821

The kinetics of methotrexate distribution in spontaneous canine lymphosarcoma.

R J Lutz, R L Dedrick, J A Straw, M M Hart, P Klubes, D S Zaharko.   

Abstract

A mathematical model is presented to simulate the time-dependent uptake of methotrexate in spontaneous canine lymphosarcomas in vivo. Blood flow ratew in these tumors are high so that transport to the tumor is limited by cell membrane resistance. A significant amount of rapidly exchangeable methotrexate appears to exist in extracellular space loosely bound to proteins or cell membranes. Transmembrane drug transport follows Michaelis-Menten kinetics, wigh the maximum facilitated transport ranging from 0.002 to 0.007 mug/min/ml for the separate tumors studied and a Michaelis constant for transport equal to 0.2 mug/ml. This is in the range of Michaelis constants reported for normal tissues in rats in vivo and in several cell linnes in vitro.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1173821     DOI: 10.1007/bf01066017

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  13 in total

1.  Distribution of anticancer agents in spontaneous animal tumors. I. Regional blood flow and methotrexate distribution in canine lymphosarcoma.

Authors:  J A Straw; M M Hart; P Klubes; D S Zaharko; R L Dedrick
Journal:  J Natl Cancer Inst       Date:  1974-04       Impact factor: 13.506

2.  Transport and binding of methotrexate in vivo.

Authors:  R L Dedrick; D S Zaharko; R J Lutz
Journal:  J Pharm Sci       Date:  1973-06       Impact factor: 3.534

3.  The mechanism of action of methotrexate. I. Interaction with a low-affinity intracellular site required for maximum inhibition of deoxyribonucleic acid synthesis in L-cell mouse fibroblasts.

Authors:  I D Goldman
Journal:  Mol Pharmacol       Date:  1974-03       Impact factor: 4.436

4.  Clinical and pathologic study of canine lymphoma: clinical staging, cell classification, and therapy.

Authors:  R A Squire; M Bush; E C Melby; L M Neeley; B Yarbrough
Journal:  J Natl Cancer Inst       Date:  1973-08       Impact factor: 13.506

5.  Methotrexate pharmacokinetics.

Authors:  K B Bischoff; R L Dedrick; D S Zaharko; J A Longstreth
Journal:  J Pharm Sci       Date:  1971-08       Impact factor: 3.534

6.  Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell.

Authors:  I D Goldman; N S Lichtenstein; V T Oliverio
Journal:  J Biol Chem       Date:  1968-10-10       Impact factor: 5.157

Review 7.  The internal milieu of tumors.

Authors:  P M Gullino
Journal:  Prog Exp Tumor Res       Date:  1966

8.  Studies with a 2,4-diamino-5-chloro-quinazoline antifolate: in vitro and invivo correlates in normal and lymphosarcoma dogs.

Authors:  E Fölsch; G Abboud; E Gralla; J R Bertino
Journal:  Ann N Y Acad Sci       Date:  1971-11-30       Impact factor: 5.691

Review 9.  Chemotherapy of neoplastic disease with folate antagonists.

Authors:  P T Condit
Journal:  Ann N Y Acad Sci       Date:  1971-11-30       Impact factor: 5.691

10.  The penetration of cytotoxins into malignant tumours.

Authors:  D C Rowe-Jones
Journal:  Br J Cancer       Date:  1968-03       Impact factor: 7.640

View more
  11 in total

Review 1.  A review of the applications of physiologically based pharmacokinetic modeling.

Authors:  K J Himmelstein; R J Lutz
Journal:  J Pharmacokinet Biopharm       Date:  1979-04

2.  A pharmacokinetic model for high-dose methotrexate infusions in man.

Authors:  S D Reich; N R Bachur; R H Goebel; M Berman
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

Review 3.  Physiologically based pharmacokinetic models for anticancer drugs.

Authors:  H S Chen; J F Gross
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Pharmacokinetics of methotrexate in solid tumors.

Authors:  R K Jain; J Wei; P M Gullino
Journal:  J Pharmacokinet Biopharm       Date:  1979-04

5.  Physiologic model for the pharmacokinetics of 2'deoxycoformycin in normal and leukemic mice.

Authors:  F G King; R L Dedrick
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

6.  Pharmacokinetics of methotrexate in leukemia cells: effect of dose and mode of injection.

Authors:  J M Weissbrod; R K Jain; F M Sirotnak
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

7.  Physiologically based pharmacokinetic models of 2',3'-dideoxyinosine.

Authors:  H J Kang; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

Review 8.  The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic.

Authors:  Qingyu Zhou; James M Gallo
Journal:  AAPS J       Date:  2011-01-19       Impact factor: 4.009

9.  The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.

Authors:  J F Smyth; R M Paine; A L Jackman; K R Harrap; M M Chassin; R H Adamson; D G Johns
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

10.  Pharmacokinetics of sulfaethidole in the rat: nonlinear multicompartment solution.

Authors:  M Kekki; R J Julkunen; H Pohjanpalo
Journal:  J Pharmacokinet Biopharm       Date:  1982-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.